To contentTo navigationTo search

Implantica presents the second quarter 2023 on August 24 at 15:00 CET

 | Non regulatory

Implantica AG (publ) invites investors to a presentation of the second quarter 2023 at 15:00 CET on August 24. The interim report for the second quarter will be published at 8:00 a.m. CET on the same day.

The presentation will be in English via an audiocast with teleconference:

If you wish to participate via webcast, please use the following link:

If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference.


  • CEO Peter Forsell
  • CFO Andreas Öhrnberg
  • Chief Corporate Affairs Officer Nicole Pehrsson

For further information, please contact:

Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB,

The information was sent for publication, through the agency of the contact person set out above, on August 18, 2023 at 08:00 a.m. CET.

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information.